The circadian clock drives cycles of energy storage and utilization in plants, flies, and mammals in anticipation of changes in the external environment imposed by the rising and setting of the sun[@R1]. In mammals, the transcription factors CLOCK and BMAL1 drive the central oscillator within the hypothalamus and even in peripheral tissues, yet a major question remains regarding the link between cellular rhythms and organismal homeostasis, including constancy of energy and fuel utilization cycles[@R8],[@R9]. In humans, one of the most pronounced rhythmic aspects of physiology involves the daily variation of glucose tolerance and insulin sensitivity across the 24 hr day, and importantly, disruption of circadian oscillation of glucose metabolism is a hallmark of type 2 diabetes[@R4]. Moreover, there is growing evidence that metabolic and circadian systems are interconnected at the transcriptional level, as genomic analyses have revealed that both neural and peripheral clocks regulate the 24 hr periodicity of RNAs that mediate rate-limiting steps in glycolysis, fatty acid oxidation, and oxidative phosphorylation, indicating that these processes are primed to occur at the optimal time during glucose and fatty acid utilization cycles[@R2],[@R10]--[@R13].

Prompted by the hypothesis that the circadian clock exerts effects on metabolism through cellular actions, we sought to dissect the impact of clock function within the pancreatic islet, a principle regulator of glucose homeostasis. We used real-time bioluminescence imaging in isolated pancreatic islets from *Period2^Luciferase^* (*Per2^Luc^*) knock-in mice to determine whether the clock is expressed autonomously within pancreas[@R14]. Continuous monitoring of light emission from individual islets revealed a self-sustained high-amplitude rhythm of PER2::LUC expression with a period length of 23.58 ± 0.3 hrs ([Fig 1a--b](#F1){ref-type="fig"} and [Suppl Movies S1](#SD6){ref-type="supplementary-material"}--[2](#SD7){ref-type="supplementary-material"}), which closely matched that of other peripheral tissues and the SCN ([Fig 1b](#F1){ref-type="fig"})[@R14],[@R15]. The oscillation gradually dampened after three days, similar to pituitary and liver ([Fig 1b](#F1){ref-type="fig"}), and addition of 10µM forskolin to islets led to immediate reinitiation of robust rhythms ([Fig 1c](#F1){ref-type="fig"}). Bioluminescence from individual islets from *Clock^Δ19/Δ19^* mutant mice lacked a circadian rhythm, even after forskolin stimulation ([Fig 1c](#F1){ref-type="fig"}). Quantitative real-time PCR showed that *Per2* RNA expression was reduced and rhythmicity abolished in islets from *Clock^Δ19/Δ19^* mutant mice ([Fig 1d](#F1){ref-type="fig"}). Together, the PER2 protein and mRNA oscillation in WT islets, as well as the loss of rhythmicity of *Per2* in *Clock^Δ19/Δ19^* islets, provide evidence for a self-sustained clock in endocrine pancreas.

Since a major mechanism of circadian regulation involves the cycling of genes involved in cell metabolism and proliferation, we examined 24 hr RNA rhythms of essential transcripts involved in insulin secretion and β-cell growth in isolated islets ([Suppl Fig 1](#SD6){ref-type="supplementary-material"}). *Clock^Δ19/Δ19^* mutant islets showed decreased expression levels of genes downstream of CLOCK:BMAL1 that comprise the core circadian loop, as well as the D-box and ROR feedback loops ([Fig 1d](#F1){ref-type="fig"}). *Clock^Δ19/Δ19^* mutant animals also showed decreased levels of expression and/or phase shifts of RNA oscillation of genes involved in insulin signaling (*InsR, Irs2, Pi3K p85, Akt2*), glucose sensing (*Glut2, Gck*), and islet growth and development (*CyclinD1, Gsk3β , Hnf4α , Hnf1α , Pdx1, NeuroD1*) ([Fig Suppl 1](#SD6){ref-type="supplementary-material"}). The alterations in temporal patterns of gene expression in *Clock^Δ19/Δ19^* mutant islets were distinct from those in *Clock^Δ19/Δ19^* mutant liver, reflecting partitioning of metabolic functions within these two tissues at different times of day ([Fig Suppl 1](#SD6){ref-type="supplementary-material"}--[2](#SD7){ref-type="supplementary-material"} and [Supporting Description 1](#SD1){ref-type="supplementary-material"}).

To determine whether molecular disruption of the clock in pancreas corresponds with abnormalities in the temporal control of glucose metabolism, we analyzed 24 hr glucose and insulin profiles in 8 month old *Clock^Δ19/Δ19^* mutant mice and their WT littermates during ad lib feeding. In *Clock^Δ19/Δ19^* mutants, glucose levels were elevated across the entire light-dark (LD) cycle without a rise in insulin levels, whereas insulin rises in WT animals during the beginning of the feeding period ([Fig 2a--b](#F2){ref-type="fig"}). *Clock^Δ19/Δ19^* mutant mice also displayed significantly elevated fasting glucose levels at both ZT2 and ZT14 ([Fig Suppl 3e--f](#SD8){ref-type="supplementary-material"}). Glucose tolerance tests further revealed a 50% reduction in insulin release, corresponding with increased glucose excursion in *Clock^Δ19/Δ19^* mutant mice particularly at the beginning of the dark period ([Fig 2c--d](#F2){ref-type="fig"} and [Supporting Description 2](#SD1){ref-type="supplementary-material"}). The likelihood that impaired glucose tolerance in *Clock^Δ19/Δ19^* mutant mice involves a primary defect in pancreatic function was further supported by the finding that these animals have normal insulin tolerance ([Fig Suppl 3c--d](#SD8){ref-type="supplementary-material"}).

To better understand the impact of the circadian gene mutation on pancreatic function, we examined glucose-stimulated insulin secretion (GSIS) in isolated size-matched pancreatic islets from 8 month old mice. Islets from *Clock^Δ19/Δ19^* mice displayed a \~50% reduction in GSIS ([Fig 3a](#F3){ref-type="fig"}) and failed to respond to KCl ([Fig 3b](#F3){ref-type="fig"}), indicating a defect in insulin exocytosis. Consistent with a predominant defect in insulin release rather than glucose metabolism, we observed normal calcium flux in response to 12 mM glucose in *Clock^Δ19/Δ19^* mutant compared to WT islets ([Fig Suppl 5d--e](#SD10){ref-type="supplementary-material"}). Further consistent with defects in exocytosis, islets from *Clock^Δ19/Δ19^* mutant mice displayed diminished insulin secretory responses to the cyclase activators forskolin and exendin-4, as well as 8-Bromo-cyclic AMP, localizing the impaired function of *Clock^Δ19/Δ19^* mutant islets to a late stage in stimulus-secretion coupling[@R16] ([Fig 3b](#F3){ref-type="fig"}). Lastly, in agreement with an exocytic defect as the cause of decreased insulin release in circadian mutant animals, we did not observe a significant difference in either absolute insulin mRNA levels ([Fig Suppl 1b](#SD6){ref-type="supplementary-material"}) or in islet insulin content (WT 38.2 ng insulin/islet vs *Clock^Δ19/Δ19^* 32.9 ng insulin/islet, p=0.08).

In contrast to 8 month old *Clock^Δ19/Δ19^* mutant mice, we found that fasting and fed glucose levels in 3 month old *Clock^Δ19/Δ19^* mutants were normal and that they had enhanced insulin sensitivity, possibly due to clock disruption at the level of either liver, skeletal muscle or adipose tissue ([Fig Suppl 4a--f](#SD9){ref-type="supplementary-material"}). Nonetheless, isolated islets even from young *Clock^Δ19/Δ19^* mutant mice displayed impaired GSIS ([Fig Suppl 4g](#SD9){ref-type="supplementary-material"}). These observations are consistent with early onset of a primary islet cell defect that only manifests as overt diabetes in \>8 month old *Clock^Δ19/Δ19^* mutants, likely due to the gradual onset of insulin resistance during aging (compare [Fig Suppl 3c,d](#SD8){ref-type="supplementary-material"} and [4e,f](#SD9){ref-type="supplementary-material"}), unmasking the β-cell defect and thereby resulting in age-associated hyperglycemia and hypoinsulinemia.

Functional defects in insulin secretion have previously been shown to arise due to impairment of genetic pathways that alter islet proliferation and survival[@R17]--[@R21]. In this regard, although indirect immunofluorescence revealed normal overall architecture of islets of *Clock^Δ19/Δ19^* mice ([Fig 3c](#F3){ref-type="fig"}), light microscopy of isolated islets revealed that *Clock^Δ19/Δ19^* mutant islets were smaller than those of WT ([Fig 3d](#F3){ref-type="fig"}). Total islet area was also reduced by \~20% in *Clock^Δ19/Δ19^* mice based upon morphometric analysis of intact pancreata, corresponding with a trend towards decreased total pancreatic insulin content ([Fig Suppl 5a--b](#SD10){ref-type="supplementary-material"}). To determine whether the observed decrease in islet size corresponded with decreased islet proliferation, we stained pancreatic sections with the proliferation marker Ki67. Surprisingly, we found a 23% decrease in proliferation in islets from *Clock^Δ19/Δ19^* mutant animals ([Fig 3e](#F3){ref-type="fig"}), together with a trend towards increased islet apoptosis ([Fig Suppl 5c](#SD10){ref-type="supplementary-material"}). Microarray analysis revealed decreased levels of genes encoding components of E-box, D-box, and ROR transcription modules (*Per1, Per3, Rev-erbα Tef, Dbp*) ([Supporting Description 3](#SD1){ref-type="supplementary-material"}, [Fig Suppl 6b](#SD11){ref-type="supplementary-material"} and [Suppl Tables 1](#SD3){ref-type="supplementary-material"}--[2](#SD4){ref-type="supplementary-material"}). Gene Ontogeny enrichment revealed significant alterations in vesicular docking and trafficking factors (including *Vamp3* and *Syntaxin6*) and increases in the cell death factor *S100a6* ([Fig Suppl 7](#SD12){ref-type="supplementary-material"} and [Supporting Description 4](#SD1){ref-type="supplementary-material"}), consistent with reduced function and size of islets from *Clock^Δ19/Δ19^* mutant mice.

To determine whether the defects of islet function and size are unique to the *Clock^Δ19/Δ19^* animal, or instead reflect a generalized role for the core circadian network in islet function, we analyzed both GSIS and islet size in *Bmal1^−/−^* mutant mice[@R7]. *Bmal1^−/−^* islets exhibited up to a 60% reduction in insulin secretion compared to littermate controls in response to glucose, KCl, exendin4, forskolin, and 8-Br-cAMP ([Fig 3f--g](#F3){ref-type="fig"}). Furthermore, there was a 2-fold reduction in the percentage of large islets in *Bmal1^−/−^* mice compared with WT littermates ([Fig 3d](#F3){ref-type="fig"}). The similarity of defects in islets from *Clock^Δ19/Δ19^* mutant and *Bmal1^−/−^* mice suggests that multiple core circadian genes impact β-cell function and development.

To further evaluate the contribution of the pancreatic clock to both whole body glucose metabolism and to islet function, we generated pancreas-specific *Bmal1* mutant mice using the promoter of the homeodomain transcription factor PDX1 to drive expression of CRE-recombinase[@R22],[@R23] ([Fig 4](#F4){ref-type="fig"}). We performed immunofluorescent staining to confirm loss of BMAL1 expression specifically within pancreatic islets ([Fig 4a](#F4){ref-type="fig"}) and not within brain regions such as the suprachiasmatic nucleus (SCN), arcuate nucleus (ARC), dorsomedial hypothalamus (DMH), and paraventricular nucleus (PVN) ([Fig 4b](#F4){ref-type="fig"} and [Fig Suppl 8](#SD13){ref-type="supplementary-material"}). Quantitative real-time PCR analysis of key circadian genes in islet and liver from *PdxCre;Bmal1^flx/flx^* and control mice revealed islet-specific alterations in gene expression profiles ([Fig 4c](#F4){ref-type="fig"} and [Supporting Description 5](#SD1){ref-type="supplementary-material"}), further confirming the specificity of the *Bmal1* mutation to the islet. Importantly, the pancreas-specific *Bmal1* knockout mice showed normal circadian activity, feeding rhythms, and body weight and composition ([Fig Suppl 8b--h](#SD13){ref-type="supplementary-material"}). Remarkably, however, we found that 2--4 month old *PdxCre; Bmal1^flx/flx^* mice displayed significantly elevated *ad lib* glucose levels throughout the day ([Fig 4d](#F4){ref-type="fig"}), as well as dramatically impaired glucose tolerance and decreased insulin secretion ([Fig 4e--f](#F4){ref-type="fig"}, [Fig Suppl 9c--d](#SD2){ref-type="supplementary-material"} and [Suppl Table 3](#SD5){ref-type="supplementary-material"}). It is important to note that these phenotypes develop in *PdxCre;Bmal1^flx/flx^* mice at a young age (2--4 mo) compared to the global *Clock^Δ19/Δ19^* mutant mice. Furthermore, the impaired glucose tolerance in the pancreas-specific *Bmal1* mutant mice was much more pronounced than in either of the global *Clock^Δ19/Δ19^* or *Bmal1* nullizygous mice, consistent with compensation occurring in the global mutant mice and emphasizing the primary role of the islet clock in maintaining euglycemia. Finally, because the pancreas-specific *Bmal1* mutant mice have normal activity and feeding rhythms, as well as normal body weight ([Fig Suppl 8](#SD13){ref-type="supplementary-material"}), the metabolic phenotypes that develop must be due to disruption of the clock network within the islet, rather than due to secondary changes in activity or behavior. Interestingly, our isolated islet studies in the pancreas-specific *Bmal1* knockout mice revealed diminished insulin responsiveness to glucose, KCl, exendin 4, forskolin, and 8-Br-cAMP, indicating a block in exocytosis ([Fig 4g--h](#F4){ref-type="fig"}), similar to that of *Clock^Δ19/Δ19^* and *Bmal1* mutant mice. Thus, ablation of the pancreatic clock is sufficient to render the islet refractory to glucose and insulin secretagogues, resulting in hyperglycemia.

The recent availability of both global and tissue-specific genetic models of circadian disruption offers unique opportunities to define the role of circadian oscillators in physiology. For instance, our previous studies in *Clock^Δ19/Δ19^* mutant mice showed that these mice are susceptible to obesity and certain features of metabolic syndrome including steatosis, adipose hypertrophy, and hyperlipidemia, due to primary defects within both hypothalamus (decreased anorexigenic peptidergic signaling), and also within liver. Yet *Clock^Δ19/Δ19^* animals have sufficient β-cell reserve early in life to drive adiposity, although eventually their weight gain plateaus coincident with progressive β-cell failure. In contrast, ablation of the clock within liver results in hypoglycemia[@R24],[@R25], while clock function within liver is also tied to reduced cholesterol extrusion as bile, steatosis, and hypertriglyceridemia, all features of metabolic syndrome[@R26]--[@R28]. In summary, obesity in circadian mutants is separable from insulin resistance, and the same defects that cause changes in β-cell function can ameliorate insulin resistance in the liver, through mechanisms that require further investigation. Our findings in β-cell conditional knockouts underscore the intimate integration of circadian and metabolic systems within multiple tissues and the complex effect of clock function in separate tissues on energy and metabolic homeostasis in the whole animal. In addition to orchestrating the daily cycles of glucose metabolism, the islet circadian transcription network also participates in the determination of islet cell mass, similar to previously reported effects of the clock on growth and regeneration of bone[@R29] and liver[@R30]. Clinical evidence further suggests that temporal defects in insulin secretion are early indicators of β-cell dysfunction. Therefore, consideration of the dynamics of clock function across temporally distinct phases of the day-night cycle, and within different tissues as the cycle progresses, may also explain obesity and metabolic pathologies that emerge in states of circadian disruption including shift work and night eating.

METHODS SUMMARY {#S1}
===============

Islet Isolation and in Vitro Insulin Secretion Analysis {#S2}
-------------------------------------------------------

Pancreatic islets were isolated and secretion assays performed as described in [Supplementary Material](#SD1){ref-type="supplementary-material"}. Briefly, for insulin release, 5 islets were statically incubated in Krebs-Ringer Buffer and stimulated for 1hr at 37°C with various glucose concentrations, 30mM KCl, 100nM exendin 4, 2.5µM forskolin, or 1mM 8-Br-cAMP.

Circadian Expression of PER2::LUC {#S3}
---------------------------------

Bioluminescence from *Per2^Luc^* and *Per2^Luc^*;*Clock^Δ19/Δ19^* islets was continuously imaged using an XR/MEGA-10Z cooled CCD camera, as islets were cultured at 37°C in a Lucite environmentally controlled chamber (full details in [Supplementary Material](#SD1){ref-type="supplementary-material"}). Period and damping rate were calculated using Lumicycle Analysis software (Actimetrics).

[Full methods]{.ul} accompany this paper.
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![Cell autonomous oscillator in pancreas\
(a) Islets from *Per2Luc* mice were imaged, and orange trace at right represents bioluminescence rhythm collected from the islet in the orange square (left). Traces from other islets are shown below. See also Supplemental Movies 1--2. (b) Periods of luminescence and damping rate in multiple tissues (mean ± S.E.M., n=6 mice/genotype). (c) Whole field and individual traces from WT and *Clock^Δ19/Δ19^* islets. Red arrow indicates exposure to 10 µM forskolin for 1 hour. (d) Oscillation of clock genes in WT and *Clock^Δ19/Δ19^* mutant islets across 24 hrs (mean ± S.E.M., n=4 mice/genotype/time point, 2-way ANOVA, \*p\<0.05).](nihms213096f1){#F1}

![Diabetic phenotypes in 8 month old circadian mutant mice\
Ad lib fed (a) glucose and (b) insulin in *Clock^Δ19/Δ19^* animals, shown as the average for time points during the light and dark periods (n=17). (c) Glucose tolerance (n=15--18) and (d) insulin secretion (n=8--10) in *Clock^Δ19/Δ19^* mice at ZT14 following intraperitoneal glucose administration of 2 or 3g/kg body weight, respectively n=15--18). Data was analyzed by Student's *t*-test (a--b) and 1-way ANOVA (c--d). p\<0.05; \*\*p\<0.01; \*\*\*p\<0.001. All values represent mean ± S.E.M.](nihms213096f2){#F2}

![Reduced islet size, proliferation, and insulin release in 8--10 month old circadian mutant mice\
(a) Glucose-stimulated insulin release in isolated *Clock^Δ19/Δ19^* islets compared to similar-sized WT islets (n=9--10 mice/genotype), normalized to % insulin content. (b) Insulin secretion from *Clock^Δ19/Δ19^* islets in response to secretagogues (n=6--14). Insulin release was calculated as in (a), and *Clock^Δ19/Δ19^* values are expressed as a percentage of WT. (c) Representative islet morphology in *Clock^Δ19/Δ19^* and WT pancreata (body weight and pancreata weight were not different). (d) Size of islets isolated from *Clock^Δ19/Δ19^* and *Bmal1^−/−^* mice compared to WT (n=6--9). (e) Ki67 staining of islet proliferation (*Clock^Δ19/Δ19^* and WT, n=5--6). (f) Glucose-stimulated insulin secretion in *Bmal1^−/−^* islets compared to WT (n=5). (g) Insulin secretion from *Bmal1^−/−^* islets in response to secretagogues (n=6--10). Five islets per mouse were analyzed in triplicate for each test condition; data was analyzed by Student's *t*-test. \*p\<0.05; \*\*p\<0.01, and values represent mean ± S.E.M.](nihms213096f3){#F3}

![Impaired glucose tolerance and islet insulin secretion in 2--4 mo old pancreas-specific circadian mutant mice\
(a) Immunofluorescent staining of BMAL1 (red), insulin (blue), and glucagon (green) in *PdxCre; Bmal1^flx/flx^* and control islets (Scale bar, 25 m). (b) Immunofluorescent staining of BMAL1 (red) and DAPI (blue) in SCN of *PdxCre; Bmal1^flx/flx^* and control mice (Scale bar, 50 µm). (c) Oscillation of *Bmal1, Rev-erbα*, and *s100a6* in islets and liver of *PdxCre; Bmal1^flx/flx^* mice at three sequential 8 hr time points (n=4 mice/genotype/time). (d) Blood glucose levels in ad lib fed *PdxCre; Bmal1^flx/flx^* mice, shown as the average for values in light and dark (n=9--10). (e) Glucose tolerance (n=6--8) and (f) insulin secretion (n=9--11) in *PdxCre; Bmal1^flx/flx^* mice at ZT2 following intraperitoneal glucose administration of 2 or 3g/kg body weight, respectively. (g) Insulin release in response to glucose in *PdxCre; Bmal1^flx/flx^* islets compared to size-matched control islets (n=5--7). (h) Insulin secretion from *PdxCre; Bmal1^flx/flx^* islets in response to secretagogues (n=5--7). For all studies, five islets per mouse were analyzed in triplicate for each concentration of glucose and secretagogue. Data was analyzed by 1-way (e,f) and 2-way (c) ANOVA, and Student's *t*-test (d,g,h). \*p\<0.05; \*\*p\<0.01; \*\*\*p\<0.001. For c,e,f, \* denotes significance between *Bmal1^flx/flx^* and *PdxCre;Bmal1^flx/flx^*, and + denotes significance between *PdxCre* and *PdxCre;Bmal1^flx/flx^*. All values represent mean ± S.E.M.](nihms213096f4){#F4}
